Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rivaroxaban

Known as: 5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)- 1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide, 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide, Rivaroxaban [Chemical/Ingredient] 
An orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with… Expand
Review
2019
Review
2019
The European Society of Cardiology (ESC) has published a series of guidelines on heart failure (HF) over the last 25 years, most… Expand
Review
2019
Review
2019
The objective was to develop evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults… Expand
Review
2019
Review
2019
Essentials We investigated direct oral anticoagulant (DOAC) use in venous thromboembolism and thrombophilia. A comprehensive… Expand
Review
2018
Review
2018
ABSTRACT The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned by clinicians worldwide due to… Expand
  • table 1
  • figure 1
  • table 2
  • table 4
  • table 5
Review
2018
Review
2018
BACKGROUND Direct oral anticoagulants (DOACs) are widely used for secondary prevention of venous thromboembolism (VTE) but their… Expand
Highly Cited
2012
Highly Cited
2012
BACKGROUND A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 3
Highly Cited
2011
Highly Cited
2011
BACKGROUND The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2010
Highly Cited
2010
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2008
Highly Cited
2008
BACKGROUND This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4